Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVO756 · 3 trials · 3 indications
Safety will be assessed by the total number of subjects with at least one TEAE
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | Orally administered EVO756, Dose 1 |
| Dose 2 | EXPERIMENTAL | Orally administered EVO756, Dose 2 |
| Dose 3 | EXPERIMENTAL | Orally administered EVO756, Dose 3 |
| Placebo | PLACEBO_COMPARATOR | Placebo control |
| Placebo control | PLACEBO_COMPARATOR | Orally administered placebo control |
| EVO756 300 mg QD | EXPERIMENTAL | Oral EVO756 300 mg QD |
| EVO756 50 mg BID | EXPERIMENTAL | Oral EVO756 50 mg BID |
| Name | Type | Description |
|---|---|---|
| EVO756 | DRUG | Dose 1 |
| Placebo control | DRUG | Placebo control |
| Oral EVO756 300 mg QD | DRUG | Oral EVO756, 300 mg once daily |
| Oral EVO756 50 mg BID | DRUG | Oral EVO756 50 mg twice daily |
Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, o...